Antiviral Therapy
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 3.3 | Q2 | 63.1% | 0.836 | Q2 | 78.8% |
| 2024 | 2.3 | Q3 | 45.3% | 0.627 | Q2 | 69.9% |
| 2023 | 1.3 | Q4 | 12.2% | 0.447 | Q3 | 61.3% |
| 2022 | 1.2 | Q4 | 7.5% | 0.460 | Q3 | 63.7% |
| 2021 | 1.7 | Q4 | 13.2% | 0.835 | Q2 | 82.3% |
| 2020 | — | — | 0.747 | Q2 | 78.0% | |
| 2019 | — | — | 0.753 | Q2 | 78.8% | |
| 2018 | — | — | 0.931 | Q2 | 82.6% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1359-6535
ISSN
2040-2058
country
GBcoverage
1996-2025